The hidden harm behind the return of results from personal genome services: A need for rigorous and responsible evaluation

Genetics in Medicine

Volumn 17, Issue 8, 2015, Pages 621-622

  Janssens, A Cecile J W ^a,b  

^a EMORY UNIVERSITY   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E;

ALZHEIMER DISEASE; DEPRESSION; EDUCATIONAL STATUS; EMOTION; EMPLOYMENT STATUS; GENETIC PREDISPOSITION; GENETIC SCREENING; GENOTYPE; HUMAN; NOTE; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE; ANXIETY; HEALTH SURVEY; INTERPERSONAL COMMUNICATION;

ANXIETY; DEPRESSION; GENETIC TESTING; HUMANS; PUBLIC HEALTH SURVEILLANCE; TRUTH DISCLOSURE;

EID: 84938693900     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2014.169     Document Type: Note

References (13)

1. Caulfield T, McGuire AL. Direct-To-consumer genetic testing: perceptions, problems, and policy responses. Annu Rev Med 2012; 63: 23-33
2. Kalf RR, Mihaescu R, Kundu S, de Knijff P, Green RC, Janssens AC. Variations in predicted risks in personal genome testing for common complex diseases. Genet Med 2014; 16: 85-91
3. Baudhuin LM. The FDA and 23andMe: violating the First Amendment or protecting the rights of consumers? Clin Chem 2014; 60: 835-837
4. Bloss CS, Schork NJ, Topol EJ. Effect of direct-To-consumer genomewide profiling to assess disease risk. N Engl J Med 2011; 364: 524-534
5. Bloss CS, Wineinger NE, Darst BF, Schork NJ, Topol EJ. Impact of directto-consumer genomic testing at long term follow-up. J Med Genet 2013; 50: 393-400
6. Francke U, Dijamco C, Kiefer AK, et al. Dealing with the unexpected: consumer responses to direct-Access BRCA mutation testing. PeerJ 2013; 1: e8
7. Kaphingst KA, McBride CM, Wade C, et al. Patients understanding of and responses to multiplex genetic susceptibility test results. Genet Med 2012; 14: 681-687
8. Hartz SM, Olfson E, Culverhouse R, et al. Return of individual genetic results in a high-risk sample: enthusiasm and positive behavioral change. Genet Med 2014; xx: xxx-xxx
9. Marteau TM, French DP, Griffin SJ, et al. Effects of communicating DNA-based disease risk estimates on risk-reducing behaviours. Cochrane Database Syst Rev 2010; 10: CD007275
10. Green RC, Farahany NA. Regulation: The FDA is overcautious on consumer genomics. Nature 2014; 505: 286-287
11. Green RC, Roberts JS, Cupples LA, et al.; REVEAL Study Group. Disclosure of APOE genotype for risk of Alzheimers disease. N Engl J Med 2009; 361: 245-254
12. de Miguel-Yanes JM, Shrader P, Pencina MJ, et al.; MAGIC Investigators; DIAGRAM+ Investigators. Genetic risk reclassification for type 2 diabetes by age below or above 50 years using 40 type 2 diabetes risk single nucleotide polymorphisms. Diabetes Care 2011; 34: 121-125
13. Johansson M, Holmström B, Hinchliffe SR, et al. Combining 33 genetic variants with prostate-specific antigen for prediction of prostate cancer: longitudinal study. Int J Cancer 2012; 130: 129-137